These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38833993)
21. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC). Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478 [TBL] [Abstract][Full Text] [Related]
22. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912 [TBL] [Abstract][Full Text] [Related]
23. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879 [TBL] [Abstract][Full Text] [Related]
24. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Morency E; Leitao MM; Soslow RA Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225 [TBL] [Abstract][Full Text] [Related]
25. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing. Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862 [TBL] [Abstract][Full Text] [Related]
27. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study. Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099 [TBL] [Abstract][Full Text] [Related]
28. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819 [TBL] [Abstract][Full Text] [Related]
29. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Lax SF; Kurman RJ Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874 [TBL] [Abstract][Full Text] [Related]
30. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases. Ruba S; Doherty D; Stewart CJR Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502 [TBL] [Abstract][Full Text] [Related]
31. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341 [TBL] [Abstract][Full Text] [Related]
32. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083 [TBL] [Abstract][Full Text] [Related]
33. Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions. Chien YW; Wang Y; Huang P; Lawson BC; Kolin DL; Chui MH; Vang R; Numan TA; Soong TR; Wang BG; Smith SA; Chen CL; Stone R; Douville C; Wang TL; Shih IM Am J Surg Pathol; 2024 Apr; 48(4):475-486. PubMed ID: 38298022 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study. Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869 [TBL] [Abstract][Full Text] [Related]
36. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related]
37. Methylomic Landscapes of Ovarian Cancer Precursor Lesions. Pisanic TR; Wang Y; Sun H; Considine M; Li L; Wang TH; Wang TL; Shih IM Clin Cancer Res; 2020 Dec; 26(23):6310-6320. PubMed ID: 32817081 [TBL] [Abstract][Full Text] [Related]
38. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151 [TBL] [Abstract][Full Text] [Related]
39. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751 [TBL] [Abstract][Full Text] [Related]
40. Tubal origin of ovarian cancer - the double-edged sword of haemoglobin. Lin SF; Gerry E; Shih IM J Pathol; 2017 May; 242(1):3-6. PubMed ID: 28054715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]